title: Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial.
abstract: OBJECTIVE
  To compare and study the dipeptidy1 peptidase-4 (DPP-4) inhibitors in combination with metformin against established combination therapies.
  
  
  METHODS
  This 16-week study was designed to compare sitagliptin versus pioglitazone as add-on therapy in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Fifty-two patients were randomized into two groups to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2) in addition to metformin. The primary efficacy end point was change in HbA1c. Secondary end points included change in fasting plasma glucose (FPG), body weight and lipid profile. Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire. Both the groups had a significant decrease in HbA1c.
  
  
  RESULTS
  There was no significant difference between mean reductions in FPG in both the groups. There was a significant decrease in the mean body weight and body mass index in group 1 in contrast to the significant increase in the same in group 2. Both the treatment groups reported a significant decrease in High-density lipoprotein (HDL-C) and Triglyceride.
  
  
  CONCLUSIONS
  Sitagliptin was well tolerated without any incidence of hypoglycemia. It was concluded that sitagliptin as an add-on to metformin is as effective and well tolerated as pioglitazone.
authors: Department of Pharmacology, Maulana Azad Medical College, New Delhi, India.
authors: Shalini
authors: S
authors: Chawla
authors: Nitin
authors: N
authors: Kaushik
authors: Narinder Pal
authors: NP
authors: Singh
authors: Raktim Kumar
authors: RK
authors: Ghosh
authors: Alpana
authors: A
authors: Saxena
keywords: DPP-4 inhibitors; add-on therapy; diabetes mellitus
references: Clin Ther. 2000 Dec;22(12):1395-409
references: 11192132
references: Drugs. 2011 Jul 30;71(11):1441-67
references: 21812507
references: Diabetes Obes Metab. 2008 Sep;10(10):959-69
references: 18201203
references: Diabetes Care. 2006 Dec;29(12):2638-43
references: 17130197
references: J Assoc Physicians India. 2007 Jul;55:477-80
references: 17907495
references: Hosp Pract (1995). 2011 Feb;39(1):7-21
references: 21441754
references: Diabet Med. 1990 Jun;7(5):445-51
references: 2142043
references: Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):167-74
references: 15386821
references: Diabetes Technol Ther. 2011 Jun;13(6):637-43
references: 21457065
references: Curr Med Res Opin. 2008 Feb;24(2):537-50
references: 18194595
references: Drugs. 2006;66(14):1863-77; discussion 1878-80
references: 17040116
references: Diabetes Obes Metab. 2011 Jul;13(7):644-52
references: 21410627
references: Diabetes Care. 2004 May;27(5):1047-53
references: 15111519
references: Indian J Med Res. 2007 Mar;125(3):217-30
references: 17496352
references: JAMA. 1999 Jun 2;281(21):2005-12
references: 10359389
references: Diabetes Obes Metab. 2007 Mar;9(2):194-205
references: 17300595
references: Diabetes Obes Metab. 2007 Sep;9(5):733-45
references: 17593236
references: Drug Saf. 2009;32(9):787-800
references: 19670918
references: Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55
references: 18435673
references: Diabetes Obes Metab. 2008 Jan;10(1):82-90
references: 18034842
references: Vasc Health Risk Manag. 2007;3(2):203-10
references: 17580730
references: Diab Vasc Dis Res. 2006 May;3(1):39-44
references: 16784180
references: Wien Klin Wochenschr. 2011 Apr;123(7-8):235-40
references: 21451952
references: Diabetes Obes Metab. 2011 Apr;13(4):366-73
references: 21226820
references: Maturitas. 2010 Apr;65(4):315-9
references: 20079586